Nordic Life Science 1
48 Q&A DAN AKSCHUTI EQUITY PARTNER/ BIOTECH ANALY
ST, PARETO SECURITIES “Early profitable companies are in the investor’s appetite” W HAT DO YOU predict will be the dominant market trend within life sciences this year? “Expected increased focus on latestage (post phase 2) and commercial-stage companies while seeing consolidation of the earlier-stage drug pipelines. We see/expect no specific disease area to receive extra strong focus, all remain interesting to investors, with a tilt towards bigger indications.” When it comes to opportunities to find funding or financing, what’s your outlook? “The answer is a bit similar to that for question 1, but as it is focused on Nordic life science companies, I would say the above is even more strongly the case here. Non-profitable companies with little cash in the bank will continue to have it tough to access capital, while commercial-stage and especially early profitable ones are in the investor’s appetite. Clear examples include recent ( January 2024) Pareto Securities transactions for the PREDICTING 2024 // FINANCING PHOTO ANNA W THORBJÖRNSSON